BioLine RX Ltd BLRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:35 AM EDT
1.71UNCH (UNCH)
Volume
69,011
52 week range
1.01 - 3.15
Loading...
  • Open1.70
  • Day High1.71
  • Day Low1.67
  • Prev Close1.71
  • 52 Week High3.15
  • 52 Week High Date10/15/21
  • 52 Week Low1.01
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap81.65M
  • Shares Out47.89M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta1.89
  • YTD % Change-16.42

KEY STATS

  • Open1.70
  • Day High1.71
  • Day Low1.67
  • Prev Close1.71
  • 52 Week High3.15
  • 52 Week High Date10/15/21
  • 52 Week Low1.01
  • 52 Week Low Date05/12/22
  • Market Cap81.65M
  • Shares Out47.89M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta1.89
  • YTD % Change-16.42

RATIOS/PROFITABILITY

  • EPS (TTM)-0.47
  • P/E (TTM)-3.64
  • Fwd P/E (NTM)-4.61
  • EBITDA (TTM)-24.713M
  • ROE (TTM)-34.03%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)5.85%

EVENTS

  • Earnings Date08/14/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On BioLine RX Ltd

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Aharon Schwartz Ph.D.
Chairman of the Board
Philip Serlin
Chief Executive Officer
Mali Zeevi
Chief Financial Officer
Ella Sorani
Vice President - Development
Abi Vainstein-Haras
Vice President-Clinical & Medical Affairs
Address
Modi'in Technology Park
2 HaMa'ayan Street
Modiin
7177871
Israel

Top Peers

SYMBOLLASTCHG%CHG
AKTX
Akari Therapeutics PLC
1.57+0.02+1.28%
INZY
Inozyme Pharma Inc
3.51+0.10+2.93%
ELYM
Eliem Therapeutics Inc
2.85-0.05-1.72%
CYT
Cyteir Therapeutics Inc
2.40-0.05-2.11%
FREQ
Frequency Therapeutics Inc
2.09+0.09+4.51%